Endotoxin-neutralizing peptides as gram-negative sepsis therapeutics.
Bacterial endotoxin [e.g. lipopolysaccharide (LPS)] can trigger systemic hyper-inflammatory that subsequently leads to multiple organ failure and lethality (gram-negative sepsis). This paper describes the development of endotoxin-neutralizing peptides that potentially treat sepsis. These peptides have been derived from bactericidal/permeability-increasing protein (BPIP), anti-microbial peptides, and leukocyte CD18 antigen and some of these peptides have been tested in clinical studies.
Wong
Kwong-Fai
KF
Department of Surgery, The University of Hong Kong, Jockey Club Clinical Research Center, 21 Sassoon Road, Pokfulam, Hong Kong. tonywkf@hku.hk
Luk
John M
JM
D000595:Amino Acid Sequence; D000818:Animals; D023181:Antimicrobial Cationic Peptides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D018821:CD18 Antigens / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D004731:Endotoxins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008969:Molecular Sequence Data; D010455:Peptides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy*
D023181:Antimicrobial Cationic Peptides; D018821:CD18 Antigens; D004731:Endotoxins; D010455:Peptides